Cargando…

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors

BACKGROUND: Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting new immune checkpoints including lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). Yet, the molecular and cellular mechanisms by whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Natoli, Marina, Hatje, Klas, Gulati, Pratiksha, Junker, Fabian, Herzig, Petra, Jiang, Zhiwen, Davydov, Iakov I, Germann, Markus, Trüb, Marta, Marbach, Daniel, Zwick, Adrian, Weber, Patrick, Seeber, Stefan, Wiese, Mark, Lardinois, Didier, Heinzelmann-Schwarz, Viola, Rosenberg, Robert, Tietze, Lothar, Mertz, Kirsten D, Umaña, Pablo, Klein, Christian, Codarri-Deak, Laura, Kao, Henry, Zippelius, Alfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628669/ https://www.ncbi.nlm.nih.gov/pubmed/36319064 http://dx.doi.org/10.1136/jitc-2022-005548

Ejemplares similares

A human receptor occupancy assay to measure anti‐PD‐1 binding in patients with prior anti‐PD‐1
por: Junker, Fabian, et al.
Publicado: (2021)

Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
por: Codarri Deak, Laura, et al.
Publicado: (2023)

A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade
por: Thommen, D.S., et al.
Publicado: (2018)

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the iPROFILER platform
por: Koelzer, V.H., et al.
Publicado: (2021)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity
por: Natoli, Marina, et al.
Publicado: (2021)

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
por: Trüb, Marta, et al.
Publicado: (2020)

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Common γ-Chain Cytokines
por: Zhang, Zi-Ning, et al.
Publicado: (2015)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in Atherosclerosis
por: Qiu, Ming-Ke, et al.
Publicado: (2015)

PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
por: Nakano, Michitaka, et al.
Publicado: (2018)

The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia—A Narrative Review
por: Mittelberger, Johanna, et al.
Publicado: (2022)

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
por: Trüb, Marta, et al.
Publicado: (2021)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells
por: Codarri Deak, Laura, et al.
Publicado: (2022)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
por: Saleh, Reem, et al.
Publicado: (2020)

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2011)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2010)

Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients
por: Xia, Qi, et al.
Publicado: (2018)

Tim-3 and PD-1 regulate CD8(+) T cell function to maintain early pregnancy in mice
por: XU, Yuan-Yuan, et al.
Publicado: (2017)

TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
por: Kato, Renpei, et al.
Publicado: (2020)

Supramolecular Photothermal Nanomedicine Mediated Distant Tumor Inhibition via PD-1 and TIM-3 Blockage
por: Huang, Tong-Yi, et al.
Publicado: (2020)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
por: Sun, Fan, et al.
Publicado: (2020)

Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms
por: Hu, Huihui, et al.
Publicado: (2023)

Characterization of age‐associated exhausted CD8(+) T cells defined by increased expression of Tim‐3 and PD‐1
por: Lee, Kyoo‐A, et al.
Publicado: (2016)

Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer
por: Kuai, Wentao, et al.
Publicado: (2020)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Yang, Riyao, et al.
Publicado: (2021)

Differences in Immune Checkpoints Expression (TIM-3 and PD-1) on T Cells in Women with Recurrent Miscarriages—Preliminary Studies
por: Zych, Michał, et al.
Publicado: (2021)

Increased TIM-3(+)PD-1(+) NK cells are associated with the disease activity and severity of systemic lupus erythematosus
por: Luo, Qing, et al.
Publicado: (2021)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells
por: Edwards, Sarah C., et al.
Publicado: (2022)

Effects of Treatment Conditions on Pd Speciation in CHA and Beta Zeolites for Passive NO(x) Adsorption
por: Pace, Robert B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_761l4n6sppthb9r6pegm8kn2ig